These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9464576)

  • 1. The use of cytokine inhibitors. A new therapeutic insight into heart failure.
    Matsumori A
    Int J Cardiol; 1997 Dec; 62 Suppl 1():S3-12. PubMed ID: 9464576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis.
    Iwasaki A; Matsumori A; Yamada T; Shioi T; Wang W; Ono K; Nishio R; Okada M; Sasayama S
    J Am Coll Cardiol; 1999 Apr; 33(5):1400-7. PubMed ID: 10193745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure.
    Matsumori A; Shioi T; Yamada T; Matsui S; Sasayama S
    Circulation; 1994 Mar; 89(3):955-8. PubMed ID: 8124835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages.
    Matsumori A; Okada I; Shioi T; Furukawa Y; Nakamura T; Ono K; Iwasaki A; Sasayama S
    Life Sci; 1996; 59(10):PL121-5. PubMed ID: 8761321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Matsumori A
    BioDrugs; 1997 Feb; 7(2):107-18. PubMed ID: 18031085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pimobendan inhibits the activation of transcription factor NF-kappaB: a mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase.
    Matsumori A; Nunokawa Y; Sasayama S
    Life Sci; 2000 Oct; 67(20):2513-9. PubMed ID: 11065173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium channel blocker-induced protection against cardiovascular damage.
    Matsumori A
    Int J Cardiol; 1997 Dec; 62 Suppl 2():S39-46. PubMed ID: 9488194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production.
    Wang WZ; Matsumori A; Yamada T; Shioi T; Okada I; Matsui S; Sato Y; Suzuki H; Shiota K; Sasayama S
    Circulation; 1997 Jan; 95(1):245-51. PubMed ID: 8994443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Roles of cytokines in the pathogenesis of heart failure].
    Matsumori A
    Nihon Rinsho; 2003 May; 61(5):745-50. PubMed ID: 12754997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of amrinone and milrinone upon myocardial inflammatory signaling.
    Chanani NK; Cowan DB; Takeuchi K; Poutias DN; Garcia LM; del Nido PJ; McGowan FX
    Circulation; 2002 Sep; 106(12 Suppl 1):I284-9. PubMed ID: 12354747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vesnarinone and amrinone reduce the systemic inflammatory response syndrome.
    Takeuchi K; del Nido PJ; Ibrahim AE; Cao-Danh H; Friehs I; Glynn P; Poutias D; Cowan DB; McGowan FX
    J Thorac Cardiovasc Surg; 1999 Feb; 117(2):375-82. PubMed ID: 9918980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial.
    Deswal A; Petersen NJ; Feldman AM; White BG; Mann DL
    Chest; 2001 Aug; 120(2):453-9. PubMed ID: 11502643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy--lessons from animal experiments.
    Matsumori A; Sasayama S
    Eur Heart J; 1995 Dec; 16 Suppl O():140-3. PubMed ID: 8682082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Positive inotropic agents. Generalities and classification].
    Vahanian A; Le Potier J; Sergent J; Michel PL; Acar J
    Ann Med Interne (Paris); 1985; 136(3):242-6. PubMed ID: 2862822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
    Fitton A; Brogden RN
    Drugs Aging; 1994 May; 4(5):417-41. PubMed ID: 8043944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.
    von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review: therapeutic concepts of congestive heart failure.
    Haustein KO
    Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):273-81. PubMed ID: 1974888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.
    von der Leyen H
    Klin Wochenschr; 1989 Jun; 67(12):605-15. PubMed ID: 2671473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
    Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.